Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.37 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Spero Therapeutics, Inc. [SPRO]
Reports for Purchase
Showing records 1 - 20 ( 47 total )
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Advances on Multiple Fronts; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem Confirmatory PIVOT-PO Phase 3 Trial Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Pipeline Milestones Imminent; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NTM-PD Development FDA Draft Guidance Finalized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued; 2Q23 Financials; Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem Pivotal Trial Special Protocol Assessment Obtained; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Still Attractive With Key Catalysts Gradually Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Poised to Progress; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cash Runway Appears Relatively Lengthy; Pipeline Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
GlaxoSmithKline Rescues Tebipenem; Adjusting PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem HBr Clinical Development Pathway Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Advances; Still Undervalued; 2Q22 Financials; Reducing PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: POLLARD N
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Complete Response Letter Issuance as Expected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tebipenem Setback Overblown; 1Q22 Financials; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential Tebipenem Approval Delay; 2021 Financials; Modulating PT to $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SPR994 Approval Decision Near-Term; Pipeline Progress; Raising PT to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Spero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SPR206 Clinical Trials Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R